newsroom.csl13d
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over ...
newsroom.csl17d
OPTIONS XII IS COMING HOME
As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the second ...
newsroom.csl14d
Global Newsroom
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL ...
newsroom.csl20d
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.